A confirmatory trial for a new Alzheimer’s disease drug is many years away, Elizabeth Tracey reports
Podcast: Download (Duration: 1:06 — 1.5MB)
Subscribe: RSS
Medicare is poised to spend millions of dollars on aducanumab, a just approved drug for Alzheimer’s disease the FDA’s own advisory panel recommended against approving. Caleb Alexander, a member of the panel and an internal medicine expert at Johns Hopkins, …